The Three C's of Customer Experience in Oncology

Posted by Pranav Srivastava on Mar 20, 2019 8:00:00 AM

Malik Kaman co-wrote this blog post with Pranav Srivastava.

During a recent client meeting, a vice president of marketing challenged my perspective on the role of customer experience in oncology. Doesn’t every manufacturer want to achieve the same fundamental customer experience? And if we’re all going for the same thing, how can this be a lever of differentiation?  


>
Read More

Is it Time to Rethink PFS?

Posted by Pranav Srivastava on Oct 30, 2017 10:59:18 AM

Vinod Nair co-wrote this blog post with Pranav Srivastava.

Since the first guidelines on surrogate endpoints came out in 2003—codifying the idea that endpoints like progression-free survival (PFS), time-to-progression (TTP) and objective response rate (ORR) could be used to gain special approval—they’ve become a mainstay in oncology trial designs, with a significant increase in the number of abstracts reporting PFS as an endpoint.


>
Read More

A Gut Check on the Role of Microbiome in Cancer

Posted by Pranav Srivastava on Jul 26, 2017 11:16:51 AM

Matt Furlow co-authored this post with Pranav Srivastava.

In the novel A Wind in the Door by Madeleine L’Engle, the main character’s younger brother gets sick when fictional symbiotic entities within his mitochondria called farandolae fail to work together to prevent illness. My co-author and I were reminded of that story as we looked for parallels for the symbiotic nature of gut flora and the notion that the gut microbiome can have significant implications on health—a promising area of research that should be on the radar of oncology companies looking to expand their portfolios.


>
Read More

Is the CAR-T Upset?

Posted by Pranav Srivastava on Dec 1, 2016 12:38:37 PM

Recently, Juno Therapeutics announced that it’s putting a clinical trial for one of its CAR (chimeric antigen receptor) T-cell therapy candidates (JCAR015) on hold, even though it remains unclear whether the patient deaths in one of its trials were drug related. Following the news, the company’s stock took a beating before Thanksgiving, dropping nearly a quarter of its value. Prior to the two patient deaths—both suffered from swelling of the brain—the broad range of neurotoxicity had been a known challenge with CAR-Ts. With the latest news, we once again are faced with questions: Is this when the shine starts to come off? Are we seeing the reality beyond the hype? 


>
Read More

ASH 2016: Have Combination Regimens Arrived Yet?

Posted by Pranav Srivastava on Nov 23, 2016 9:20:07 AM


In a few short years, the treatment landscape for patients with hematologic malignancies has been transformed into a world of choices. The upcoming American Society of Hematology (ASH) Annual Meeting, which will be held Dec. 3-6 in San Diego, will bring more data to the forefront—with much more to come in the next five years—that builds on the recent trend of attacking cancer via multiple pathways through combination therapy regimens.

So far, the event abstracts already show a wide array of combination therapies in most tumor types: acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia, among many others. As the data for combination regimens continues to build, we expect many more approvals in the next few years, and with this ever-lengthening list of combination therapies comes greater hope for patients.


>
Read More